What You Need to Know about New RSV Immunizations for Children and Adults

• Jefferson Jones, MD, MPH, FAAP, Medical Epidemiologist in the United States Public Health Service and the Center for Disease Control and Prevention
• Michael Melgar, MD, Medical Officer Coronavirus and Other Respiratory Viruses Division
• Cheryl De Pinto, MD, MPH, FAAP, Senior Vice President, Primary Care and Subspecialty Pediatrics, American Academy of Pediatrics
• Moderator: L.J Tan, MS, PhD, Chief Policy and Partnerships Officer, Immunize.org

During this webinar, CDC experts provided an overview of the burden of RSV on pediatric and older adult populations, and shared information about the new ACIP recommendations for protecting adults 60 years of age and older against RSV. They also discussed the new ACIP recommendations about the new long-acting monoclonal antibody to protect infants from RSV. An expert from AAP advised providers on proper billing and coding for administering the long-acting monoclonal antibody.

Download the webinar slides (PDF):

• Clinical Considerations for Maternal RSVPreF Vaccine and Nirsevimab
• New Respiratory Syncytical Virus (RSV) Vaccines for Older Adults: General Information and Clinical Guidance
• Implementation Challenges Nirsevimab Payment and Coding Issues